Trial Profile

A retrospective observational study of monotherapy outcomes on the efficacy of third-line or later treatment for patients with HER2 positive unresectable recurrent or metastatic gastric cancer previously treated with trastuzumab

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Nivolumab (Primary) ; Tipiracil/trifluridine (Primary)
Indications Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
11 Oct 2021 Status changed from active, no longer recruiting to completed.
12 Feb 2021 Planned End Date changed from 30 Sep 2020 to 30 Oct 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com